MIGUEL ANGEL GOMEZ BRAVO

Dr. MIGUEL ANGEL GOMEZ BRAVO

orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2014 in Journal of Hepatology
Verified
Journal Article
Closed access
JBJavier Briceño
Javier Briceño
MCManuel Cruz-Ramírez
Manuel Cruz-Ramírez
MPMario Prieto-Velasco
Mario Prieto-Velasco
MNMiguel Navasa
Miguel Navasa
JUJorge Ortiz de Urbina
Jorge Ortiz de Urbina
MMManuel de la Mata
Manuel de la Mata

1 September 2001 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
CLCarlos Lumbreras
Carlos Lumbreras
FSFrancisca Sanz
Francisca Sanz
AGAlmudena González
Almudena González
GPGloria Pérez
Gloria Pérez
MRMaría J. Ramos
María J. Ramos
ANAntonio R. Noriega
Antonio R. Noriega
We evaluated the clinical significance of unrecognized bacteremia in the organ donor (i.e., blood culture results that were reported to be positive a

14 April 2014 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
JPJ. M. Pascasio
J. M. Pascasio
IGI. Grilo
I. Grilo
FLF. J. López‐Pardo
F. J. López‐Pardo
FOF. Ortega-Ruiz
F. Ortega-Ruiz
JTJ. L. Tirado
J. L. Tirado
AGA. Grilo
A. Grilo
The prevalence of hepatopulmonary syndrome (HPS) and its influence on survival before and after liver transplantation (LT) remain controversial. Additionally, the chronology of post‐LT reversibility is unclear. This study prospectively analyzed 316 patients with cirrhosis who were evaluated for LT in 2002–2007; 177 underwent LT at a single reference hospital. HPS was defined by a partial pressure of arterial oxygen (PaO2) <70 mmHg and/or an alveolar‐arterial oxygen gradient (A‐a PO2) ≥20 mmHg in the supine position and positive contrast echocardiography. The prevalence of HPS was 25.6% (81/316 patients), and most patients (92.6%) had mild or moderate HPS. High Child‐Pugh scores and the presence of ascites were independently associated with HPS. Patients with and without HPS did not significantly differ in LT waiting list survival (mean 34.6 months vs. 41.6 months, respectively; log‐rank, p = 0.13) or post‐LT survival (mean 45 months vs. 47.6 months, respectively; log‐rank, p = 0.62). HPS was reversed in all cases within 1 year after LT. One‐fourth of the patients with cirrhosis who were evaluated for LT had HPS (mostly mild to moderate); the presence of HPS did not affect LT waiting list survival. HPS was always reversed after LT, and patient prognosis did not worsen.

1 September 2009 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
RGRaúl González
Raúl González
GFGustavo Ferrin
Gustavo Ferrin
AHAna B. Hidalgo
Ana B. Hidalgo
IRIsidora Ranchal
Isidora Ranchal
PLPedro López-Cillero
Pedro López-Cillero
JMJordi Muntané
Jordi Muntané

1 June 2015 in Clinica Chimica Acta
Verified
Journal Article
Closed access
ALAntonio Leon-Justel
Antonio Leon-Justel
JNJose A. Noval-Padillo
Jose A. Noval-Padillo
AAAna I. Alvarez-Rios
Ana I. Alvarez-Rios
PMPatricia Mellado
Patricia Mellado
MBMIGUEL ANGEL GOMEZ BRAVO
MIGUEL ANGEL GOMEZ BRAVO
JGJuan M. Guerrero
Juan M. Guerrero

3 February 2017 in Liver Transplantation
Verified
Journal Article
Closed access
PDF file
DDDelia D'AVola
Delia D'AVola
VCValentín Cuervas‐Mons
Valentín Cuervas‐Mons
JMJosep Martí
Josep Martí
JUJorge Ortiz de Urbina
Jorge Ortiz de Urbina
LLLaura Lladó
Laura Lladó
JHJosé Ignacio Herrero
José Ignacio Herrero